オプションチェーンは、Amdocsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Amdocsの市場センチメントを評価します。.

Amdocs (NASDAQ:DOX) 株価情報, オプションチェーン

Amdocs

Amdocs Ltd is a provider of software and services to communications, cable and satellite, entertainment, and media industry service providers. The Company and its subsidiaries operate in one operating segment, providing software products and services for the communications, entertainment and media industry service being designed, develop, market, support, implement, and operate its open and modular cloud offering. The company offers business support systems, operational support systems, and managed services. Geographically, it derives a majority of revenue from North America and also has a presence in Europe and the Rest of the world.

Amdocs Limited

Amdocs Ltd

Doximity Inc

<p><i><strong>Greenland's largest telecom provider upgrades its business support systems (BSS) to enhance agility, unlock new revenue streams, and improve customer experience</strong></i></p>
<p><strong>JERSEY CITY, NJ / </strong><a href="https://www.accessnewswire.com/"><strong>ACCESS Newswire</strong></a><strong> / February 4, 2025 / </strong>Amdocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>), a leading provider of software and services for communications and media companies, announced today that Tusass, Greenland's largest telecom provider, has selected Amdocs to modernize its convergent charging and billing platform. This strategic upgrade marks a milestone in Tusass' digital transformation journey, paving the way for improved scalability, flexibility, and operational efficiency. As part of this transformation, Tusass will transition to a fully virtualized environment, equipping it to meet the growing demand for advanced services.</p>


News

Tusass Selects Amdocs To Modernize Monetization Platform And Unlock New Opportunities In Greenland

<p><strong>Amdocs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>) announced its Q1 earnings on Tuesday, February 4, 2025 at 04:01 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Amdocs beat estimated earnings by 1.0%, reporting an EPS of $1.66 versus an estimate of $1.64.</p>
<p>Revenue was down $135.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed on EPS by $0.0 which was followed by a 5.0% drop in the share price the next day.</p>
<p>Here's a look at Amdocs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.7</td>
<td>1.60</td>
<td>1.57</td>
<td>1.56</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.7</td>
<td>1.62</td>
<td>1.56</td>
<td>1.56</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.26B</td>
<td>1.25B</td>
<td>1.25B</td>
<td>1.25B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.26B</td>
<td>1.25B</td>
<td>1.25B</td>
<td>1.25B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Amdocs management provided guidance for Q2 2025, expecting earnings between $1.67 and $1.73 per share.</p>
<p>To track all earnings releases for Amdocs <a href="https://www.benzinga.com/quote/DOX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

Amdocs Q1 Earnings Assessment

<p><strong>Amdocs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>) announced its Q1 earnings on Tuesday, February 4, 2025 at 04:01 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Amdocs beat estimated earnings by 1.0%, reporting an EPS of $1.66 versus an estimate of $1.64.</p>
<p>Revenue was down $135.00 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.0, leading to a 5.0% drop share price change the next day.</p>
<p>Here's a look at Amdocs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.7</td>
<td>1.60</td>
<td>1.57</td>
<td>1.56</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.7</td>
<td>1.62</td>
<td>1.56</td>
<td>1.56</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.26B</td>
<td>1.25B</td>
<td>1.25B</td>
<td>1.25B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.26B</td>
<td>1.25B</td>
<td>1.25B</td>
<td>1.25B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Amdocs management provided guidance for Q2 2025, expecting earnings between $1.67 and $1.73 per share.</p>
<p>To track all earnings releases for Amdocs <a href="https://www.benzinga.com/quote/DOX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Amdocs Earnings Report: Q1 Overview

<p><strong>Amdocs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>) released its Q1 earnings on Tuesday, February 4, 2025 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Amdocs beat estimated earnings by 1.0%, reporting an EPS of $1.66 versus an estimate of $1.64.</p>
<p>Revenue was down $135.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company missed on EPS by $0.0 in the last quarter, resulting in a 5.0% drop share price change the following day.</p>
<p>Here's a look at Amdocs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.7</td>
<td>1.60</td>
<td>1.57</td>
<td>1.56</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.7</td>
<td>1.62</td>
<td>1.56</td>
<td>1.56</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.26B</td>
<td>1.25B</td>
<td>1.25B</td>
<td>1.25B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.26B</td>
<td>1.25B</td>
<td>1.25B</td>
<td>1.25B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Amdocs management provided guidance for Q2 2025, expecting earnings between $1.67 and $1.73 per share.</p>
<p>To track all earnings releases for Amdocs <a href="https://www.benzinga.com/quote/DOX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: Amdocs Q1

<p><strong>Amdocs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>) released its Q1 earnings on Tuesday, February 4, 2025 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Amdocs beat estimated earnings by 1.0%, reporting an EPS of $1.66 versus an estimate of $1.64.</p>
<p>Revenue was down $135.00 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>In the previous quarter, the company missed on EPS by $0.0, resulting in a 5.0% drop change in the share price the following day.</p>
<p>Here's a look at Amdocs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.7</td>
<td>1.60</td>
<td>1.57</td>
<td>1.56</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.7</td>
<td>1.62</td>
<td>1.56</td>
<td>1.56</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.26B</td>
<td>1.25B</td>
<td>1.25B</td>
<td>1.25B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.26B</td>
<td>1.25B</td>
<td>1.25B</td>
<td>1.25B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Amdocs management provided guidance for Q2 2025, expecting earnings between $1.67 and $1.73 per share.</p>
<p>To track all earnings releases for Amdocs <a href="https://www.benzinga.com/quote/DOX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Amdocs: Q1 Earnings Insights

Guidance

Amdocs Sees Q2 Adj. EPS $1.67-$1.73 Vs $1.68 Est; Revenue $1.105B-$1.145B Vs $1.120B Est.

<p><strong>Amdocs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>) just disclosed its Q1 earnings on Tuesday, February 4, 2025 at 04:01 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Amdocs beat estimated earnings by 1.0%, reporting an EPS of $1.66 versus an estimate of $1.64.</p>
<p>Revenue was down $135.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company missed on EPS by $0.0 in the last quarter, resulting in a 5.0% drop share price change the following day.</p>
<p>Here's a look at Amdocs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.7</td>
<td>1.60</td>
<td>1.57</td>
<td>1.56</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.7</td>
<td>1.62</td>
<td>1.56</td>
<td>1.56</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.26B</td>
<td>1.25B</td>
<td>1.25B</td>
<td>1.25B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.26B</td>
<td>1.25B</td>
<td>1.25B</td>
<td>1.25B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Amdocs management provided guidance for Q2 2025, expecting earnings between $1.67 and $1.73 per share.</p>
<p>To track all earnings releases for Amdocs <a href="https://www.benzinga.com/quote/DOX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Amdocs Q1

<p>Amdocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>) reported quarterly earnings of $1.66 per share which beat the analyst consensus estimate of $1.63 by 1.84 percent. This is a 6.41 percent increase over earnings of $1.56 per share from the same period last year.  The company reported quarterly sales of $1.110 billion which missed the analyst consensus estimate of $1.114 billion by 0.33 percent.  This is a 10.84 percent decrease over sales of $1.245 billion the same period last year.</p>


Earnings Beats

Earnings Misses

Amdocs Q1 2025 Adj. EPS $1.66 Beats $1.63 Estimate, Sales $1.110B Miss $1.114B Estimate

ALGT

AMCR

AMGN

APAM

ARMK

ATEN

ATKR

AUDC

AVNW

AXTA

AZEK

AZPN

BALL

BERY

COLM

CRUS

CVRX

EGHT

ENPH

ENVA

FICO

FLNG

FOXA

GBDC

GOOG

GOOGL

HLNE

HUBB

ICHR

IESC

INGR

INMD

INNV

INTA

JKHY

JNPR

KLIC

KTCC

LANC

LARK

LUMN

MDLZ

MLAB

MPLX

MRCY

MSGS

MTCH

MUFG

OCSL

OSCR

PINC

PYPL

RACE

Earnings Scheduled For February 4, 2025

<p>Barclays  analyst Tavy Rosner   maintains Amdocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>) with a Overweight and lowers the price target from $113 to $111.</p>


Price Target

Analyst Ratings

Barclays Maintains Overweight on Amdocs, Lowers Price Target to $111

WIIM

Amdocs shares are trading lower after the company reported worse-than-expected Q4 revenue results.

<p>Oppenheimer  analyst Timothy Horan   maintains Amdocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>) with a Outperform and raises the price target from $98 to $105.</p>


Oppenheimer Maintains Outperform on Amdocs, Raises Price Target to $105

<p><i><strong>Following successful completion of its business support systems transformation, expansion and extension of existing agreement supports Vodafone Italy's commitment to bringing next-generation services and experiences to its customers</strong></i></p>
<p><strong>JERSEY CITY, NJ / ACCESSWIRE / November 12, 2024 / </strong>Amdocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>), a leading provider of software and services to communications and media companies, today announced a five-year extension of its strategic collaboration with Vodafone Italy. Under the new agreement, Amdocs will modernize the Italian service provider's business platform to cloud-ready and cloud-native solutions, and migrate the operator's business support systems environment to the Microsoft Azure cloud.</p>
<p>Designed to empower Vodafone Italy to deliver faster, high-quality and next-generation services and experiences to its customers, this new collaboration will also enable the service provider to enhance operational efficiency and reduce costs. As part of the project, Amdocs will also continue to support Vodafone Italy's ongoing modernization of its IT systems.</p>


Global

Vodafone Italy Extends And Expands Relationship With Amdocs To Modernize And Migrate Its Systems To The Cloud, Improving Operational Efficiency And Empowering New Innovative Services

<p>Amdocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>) reported quarterly earnings of $1.70 per share which met the analyst consensus estimate.  The company reported quarterly sales of $1.264 billion which missed the analyst consensus estimate of $1.266 billion by 0.17 percent.  This is a 1.69 percent increase over sales of $1.243 billion the same period last year.</p>


Amdocs Q4 2024 Adj. EPS $1.70, Inline, Sales $1.264B Miss $1.266B Estimate

<p>Amdocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>) reported quarterly sales of $5.005 billion which beat the analyst consensus estimate of $5.002 billion by 0.06 percent.</p>


Amdocs FY Sales $5.005B Beat $5.002B Estimate

<p>The collaboration will support the Brazilian operator's microservices strategy and systems evolution, enabling Vivo to develop and introduce new services quickly and simply.</p>
<p><br />&nbsp;</p>


Amdocs Selected By Vivo To Advance Microservices Strategy And Streamline Operations

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

<p>Stifel  analyst Shlomo Rosenbaum   initiates coverage on Amdocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>) with a Buy rating and announces Price Target of $100.</p>


Initiation

Stifel Initiates Coverage On Amdocs with Buy Rating, Announces Price Target of $100

<p><i><strong>Milestone enables Vodafone Ireland to deliver superior customer experiences and operational excellence through a consolidated customer view and simplified architecture</strong></i></p>
<p><strong>JERSEY CITY, NJ / ACCESSWIRE / September 19, 2024 / </strong>Amdocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>), a leading provider of software and services to communications and media companies, today announced the successful completion of a unified single business support system (BSS) and operations support system (OSS) platform transformation for Vodafone Ireland, integrating mobile and fixed communication services into a single, streamlined system, enhancing operational efficiency and customer experience.</p>
<p>The new platform provides a consolidated customer view, empowering front-line agents to make informed decisions, reducing errors, and streamlining processes. This transformation leads to a more automated, quicker, and consistent customer journey.</p>


Vodafone Ireland Completes Unified Platform Transformation With Amdocs, Enhancing Customer Experience And Operational Efficiency

Amdocs ( ($DOX) ) has issued an update. Amdocs Limited announced its upcoming annual general meeting scheduled for January 31, 2025, to cover sever...

Amdocs Schedules 2025 Annual General Meeting with Key Proposals

Dividend Champion, Contender, And Challenger Highlights: Week Of December 29

Palm Valley Capital Fund Q4 2024 Commentary

BSMC: New Small Value ETF Lagging Its Peers

Dividend Champion, Contender, And Challenger Highlights: Week Of January 26

Stifel noted that Reuters reported this morning that Japan's NEC is considering making a bid for CSG Systems (CSGS) and that talks between the two ...

Stifel wouldn't anticipate antitrust issues with CSG Systems, NEC combo

Amdocs Non-GAAP EPS of $1.66 beats by $0.02, revenue of $1.11B in-line

Reaffirms FY25 revenue pro forma view up 1%-4.5% from last year. Consensus is for FY25 EPS $6.97 and for revenue $4.52B. Key assumptions include: r...

Amdocs reaffirms FY25 non-GAAP EPS view up 6.5%-10.5% vs. last year

Sees Q2 revenue $1.105B-$1.145B, consensus $1.12B. Q2 revenue guidance assumes a negative $3M sequential impact from foreign currency fluctuations ...

Amdocs sees Q2 non-GAAP EPS $1.67-$1.73, consensus $1.71

Reports Q1 revenue $1.110B, consensus $1.11B. "FY25 is off to a solid start. Q1 revenue of $1.11B was slightly above the midpoint of guidance adjus...

Amdocs reports Q1 non-GAAP EPS $1.66, consensus $1.64

ALLE

APOG

ARES

AVGO

Comments

Amdocs

Amdocs (DOX) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル